Economic burden of cancer does not stop after treatment
the ONA take:
According to a new study released online and being presented at the upcoming ASCO Annual Meeting in Chicago, IL, researchers have found that the economic burden of cancer extends into survivorship.
Specifically, cancer survivors deal with excess medical expenses, employment disability, and reduced production at work.
For the study, researchers analyzed the economic burden among elderly and nonelderly survivors with breast, colorectal, and prostate cancer in the United States using data from the Medical Expenditure Panel Survey between 2008 and 2012.
Researchers identified 1,568 female breast cancer survivors, 540 colorectal cancer survivors, and 1,170 prostate cancer survivors and compared their expenditures, productivity loss at work, and productivity loss at home to 100,000 people without a cancer history.
Results showed that elderly and nonelderly patients had between $9,278 and $20,238 of total annual economic burden depending on cancer type.
Nonelderly survivors of breast and colorectal cancer lost 3 and 7 days worth of productivity at work, respectively, and 3 and 5 days worth of productivity at home, respectively.
The economic burden of cancer extends into survivorship
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|